The Group senior management and the newly-established Board of Directors attach great importance to our development strategy and core business growth. Meetings are organized to discuss the strategic positioning and development concept of the company.

 

On August 27^th, 2008, the Group senior management is briefed of the company’s mid-long term development program. They highly appraised our program, especially our objectives of “engaging in the pharmaceutical investment and the build investment fund”.

The senior management points out that, the Group will support the idea of pharmaceutical investment fund; the company shall take as its priority “to engage in the pharmaceutical investment and build the investment fund”, while emancipate the mind and accelerate the process; to tap our experiences and advantages in investment and import & export business, strengthen our core business; to enhance cooperation with sister companies and become a platform of the Group in operating and serving the import & export business.

 

For investing in the pharmaceutical industry, we have abundant experience for the past three decades, built joint ventures which generated for us considerable profit, including Xi'an-Janssen Pharmaceutical Ltd, China Otsuka Pharmaceutical Co., Ltd, Sino-American Shanghai Squibb Pharmaceutical Ltd, Suzhou Capsugel, Ltd, Sino-Swede Pharmaceutical Corp. Ltd, Qingdao Huazhong Pharmaceutical Ltd.

We will make full use of our investment experiences and abundant capitals to build an investment operational platform with strategic partners, to make our contribution to the advancement of Chinese pharmaceutical industry.